Celularity (NASDAQ:CELU) Shares Down 2.3% – Here’s Why

Celularity, Inc. (NASDAQ:CELU) shares dropped 2.3% on Tuesday . The stock traded as low as $1.25 and last traded at $1.27. Approximately 74,382 shares were traded during mid-day trading, an increase of 139% from the average daily volume of 31,069 shares. The stock had previously closed at $1.30.

Celularity Price Performance

The company has a 50-day simple moving average of $1.36 and a 200-day simple moving average of $2.06. The firm has a market cap of $36.63 million, a PE ratio of -0.38 and a beta of 0.80.

Celularity (NASDAQ:CELU) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.62. The business had revenue of $5.28 million for the quarter.

Institutional Trading of Celularity

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in Celularity by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock valued at $178,000 after purchasing an additional 20,876 shares during the period. Vanguard Group Inc. increased its holdings in Celularity by 35.3% during the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after buying an additional 176,518 shares during the period. Yorkville Advisors Global LP purchased a new position in Celularity during the third quarter valued at approximately $207,000. Bank of America Corp DE raised its stake in Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after buying an additional 11,057 shares during the period. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.